🔴 Lantern Pharma is trading 5.61% down on October 7, 2026 as biotech stocks faced pressure

Lantern Pharma is trading at $0.90, down 5.61%, amid biotech-sector weakness.

• No October 7, 2026 company-specific announcement was identified; the latest listed release, dated September 30, concerned a registered direct offering of up to $8 million.
• XBI was down 2.50% during the session; another update cited elevated Treasury yields pressuring rate-sensitive biotech stocks.
• High yields, oil prices, and pending Fed minutes added broader risk-off context, not a confirmed company-specific catalyst.